<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644240</url>
  </required_header>
  <id_info>
    <org_study_id>0095</org_study_id>
    <nct_id>NCT01644240</nct_id>
  </id_info>
  <brief_title>A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the
      safety, tolerability, and pharmacokinetics (PK) of repeated IV doses of TD-8954 in healthy
      adults 18 to 45 years of age and healthy elderly subjects 65 to 85 years old. A healthy
      elderly subject population is included to evaluate the safety, tolerability, and PK of
      TD-8954 IV. Pharmacodynamic effects on bowel movements will also be evaluated. Screening for
      all cohorts will be conducted within 21 days before the first dose.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    For business reasons
  </why_stopped>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum concentration in plasma following dosing on Day 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½</measure>
    <time_frame>Day 1</time_frame>
    <description>Time to 50% plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration time curve through 24 hours after dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the concentration time curve from time 0 to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration time curve over the dosing interval estimated using the linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Vz</measure>
    <time_frame>Day 1</time_frame>
    <description>Volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma CL</measure>
    <time_frame>Day 1</time_frame>
    <description>Plasma clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 5</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 5</time_frame>
    <description>Time to reach maximum plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½</measure>
    <time_frame>Day 5</time_frame>
    <description>Time to 50% plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>Day 5</time_frame>
    <description>Area under the plasma concentration time curve 24 hours following the last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day 5</time_frame>
    <description>Area under the plasma concentration time curve from 0 to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Day 5</time_frame>
    <description>Area under the plasma concentration time curve over the dosing interval estimated using the linear trapezoidal rule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vss</measure>
    <time_frame>Day 5</time_frame>
    <description>Apparent volume of distribution at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CLss</measure>
    <time_frame>Day 5</time_frame>
    <description>Apparent clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Gastrointestinal Motility Disorder</condition>
  <arm_group>
    <arm_group_label>TD-8954 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-8954 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-8954</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>TD-8954 Dose 1</arm_group_label>
    <arm_group_label>TD-8954 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - saline</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For Cohorts 1: adult males and females age 18 to 45 years, inclusive; for Cohorts 2
             and 3, adult males and females 65 to 85 years of age, inclusive; for Cohort 4, adult
             males and females 18 to 45 or 65 to 85 years of age, inclusive.

          2. Body mass index (BMI)between 18 to 36 kg/m2, inclusive.

          3. Average frequency of ≥ 3 bowel movements per week.

        Exclusion Criteria:

          1. Persistent symptoms of functional GI disorder (such as irritable bowel syndrome,
             functional constipation, functional dyspepsia, or other symptom-based GI disorders
             unexplained by a pathologically based disorder) during the 6 months prior to
             screening, including a history of major surgery of the GI tract, excluding
             cholecystectomy and appendectomy.

          2. History or presence of clinically significant respiratory, GI, renal, hepatic,
             endocrine, hematological, neurological (including chronic headache, current or prior
             psychiatric disease/condition, stroke), cardiovascular, psychiatric, musculoskeletal,
             genitourinary, immunological, or dermatological disorders. Subjects with mild,
             chronic, stable disease (e.g., controlled hypertension, controlled
             hypercholesterolemia, non insulin-dependent diabetes, osteoarthritis) may be enrolled
             if the condition is well controlled and not anticipated to interfere with the
             objectives of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett Haumann, SVP, Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma, US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <results_first_submitted>December 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TD-8954 Dose 1</title>
          <description>TD-8954: Intravenous infusion</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo - saline: Intravenous infusion</description>
        </group>
        <group group_id="P3">
          <title>TD-8954 Dose 2</title>
          <description>TD-8954: Intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TD-8954 Dose 1</title>
          <description>TD-8954: Intravenous infusion</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo - saline: Intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>TD-8954 Dose 2</title>
          <description>TD-8954: Intravenous infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="4.92"/>
                    <measurement group_id="B2" value="37.0" spread="3.56"/>
                    <measurement group_id="B3" value="30.2" spread="5.98"/>
                    <measurement group_id="B4" value="32.6" spread="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum concentration in plasma following dosing on Day 1</description>
        <time_frame>Day 1</time_frame>
        <population>Sample size was 6 at all time points with the exception of 0.5 hours for dose 2 where value was considered an outlier and one subject was excluded from the PK analysis resulting in sample size of 5.</population>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum concentration in plasma following dosing on Day 1</description>
          <population>Sample size was 6 at all time points with the exception of 0.5 hours for dose 2 where value was considered an outlier and one subject was excluded from the PK analysis resulting in sample size of 5.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6920" spread="2120"/>
                    <measurement group_id="O3" value="1200" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to maximum plasma concentration</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to maximum plasma concentration</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.500" upper_limit="0.983"/>
                    <measurement group_id="O3" value="0.887" lower_limit="0.500" upper_limit="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t½</title>
        <description>Time to 50% plasma concentration</description>
        <time_frame>Day 1</time_frame>
        <population>Subjects did not meet extrapolation criteria and were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>t½</title>
          <description>Time to 50% plasma concentration</description>
          <population>Subjects did not meet extrapolation criteria and were not included in the analysis.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="1.22"/>
                    <measurement group_id="O3" value="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24</title>
        <description>Area under the plasma concentration time curve through 24 hours after dosing.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24</title>
          <description>Area under the plasma concentration time curve through 24 hours after dosing.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41500" spread="2740"/>
                    <measurement group_id="O3" value="12800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞</title>
        <description>Area under the concentration time curve from time 0 to infinity.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>Area under the concentration time curve from time 0 to infinity.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50600" spread="5440"/>
                    <measurement group_id="O3" value="15300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCtau</title>
        <description>Area under the plasma concentration time curve over the dosing interval estimated using the linear trapezoidal rule.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUCtau</title>
          <description>Area under the plasma concentration time curve over the dosing interval estimated using the linear trapezoidal rule.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37600" spread="7070"/>
                    <measurement group_id="O3" value="8180" spread="2610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Vz</title>
        <description>Volume of distribution</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Vz</title>
          <description>Volume of distribution</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="9.37"/>
                    <measurement group_id="O3" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma CL</title>
        <description>Plasma clearance</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma CL</title>
          <description>Plasma clearance</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" spread="1.03"/>
                    <measurement group_id="O3" value="6.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax</title>
        <description>Maximum plasma concentration</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum plasma concentration</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7070" spread="1550"/>
                    <measurement group_id="O3" value="7600" spread="1650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events</title>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>Time to reach maximum plasma concentration.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time to reach maximum plasma concentration.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.500" upper_limit="1.02"/>
                    <measurement group_id="O3" value="0.983" lower_limit="0.500" upper_limit="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t½</title>
        <description>Time to 50% plasma concentration</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>t½</title>
          <description>Time to 50% plasma concentration</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="3.18"/>
                    <measurement group_id="O3" value="18.9" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-24</title>
        <description>Area under the plasma concentration time curve 24 hours following the last dose.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24</title>
          <description>Area under the plasma concentration time curve 24 hours following the last dose.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51000" spread="9310"/>
                    <measurement group_id="O3" value="63300" spread="11800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞</title>
        <description>Area under the plasma concentration time curve from 0 to infinity.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>Area under the plasma concentration time curve from 0 to infinity.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80400" spread="15700"/>
                    <measurement group_id="O3" value="102000" spread="12300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUCtau</title>
        <description>Area under the plasma concentration time curve over the dosing interval estimated using the linear trapezoidal rule.</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AUCtau</title>
          <description>Area under the plasma concentration time curve over the dosing interval estimated using the linear trapezoidal rule.</description>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68700" spread="12700"/>
                    <measurement group_id="O3" value="86300" spread="12800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vss</title>
        <description>Apparent volume of distribution at steady state</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Vss</title>
          <description>Apparent volume of distribution at steady state</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225" spread="68.1"/>
                    <measurement group_id="O3" value="194" spread="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CLss</title>
        <description>Apparent clearance</description>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TD-8954 Dose 1</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo - saline: Intravenous infusion</description>
          </group>
          <group group_id="O3">
            <title>TD-8954 Dose 2</title>
            <description>TD-8954: Intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>CLss</title>
          <description>Apparent clearance</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="2.00"/>
                    <measurement group_id="O3" value="8.11" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TD-8954 Dose 1</title>
          <description>TD-8954: Intravenous infusion</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo - saline: Intravenous infusion</description>
        </group>
        <group group_id="E3">
          <title>TD-8954 Dose 2</title>
          <description>TD-8954: Intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brett Haumann, SVP, Clinical Development</name_or_title>
      <organization>Theravance Biopharma US, Inc.</organization>
      <phone>650-808-6000</phone>
      <email>BHaumann@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

